Figure 6.

BV6/DAC combination treatment bypasses apoptosis resistance via a switch to necroptosis. (a) Cells were treated for 6 h (MV4-11) or 48 h (NB4) with BV6 and DAC (MV4-11: 600 nM BV6, 30 nM DAC; NB4: 100 nM BV6, 50 nM DAC) in the presence or absence of 20 μM zVAD.fmk. ROS production was determined by CellROX staining and flow cytometry, and is shown as fold increase. (b) MV4-11 cells were treated for 6 h with BV6 and DAC (MV4-11: 600 nM BV6, 30 nM DAC) in the presence or absence of 20 μM zVAD.fmk with or without pretreatment with 10 mM NAC for 24 h. Cell death was determined by FSC/SSC and fluorescence-activated cell sorting analysis. (c and d) Cells were treated for 6 h (MV4-11, Molm13) or 48 h (NB4) with BV6 and DAC (MV4-11: 600 nM BV6, 30 nM DAC; NB4: 100 nM BV6, 50 nM DAC; Molm13: 400 nM BV6, 100 nM DAC) in the presence of 20 μM zVAD.fmk and/or 30 μM Nec-1 (c), or 1 μM NSA (d). Cell death was determined by FSC/SSC and FACS analysis. Mean and SD of at least three experiments performed in triplicate are shown; *P<0.05; **P<0.01; n.s., not significant